Skip to main content
. Author manuscript; available in PMC: 2021 Mar 17.
Published in final edited form as: Obstet Gynecol. 2018 Mar;131(3):431–439. doi: 10.1097/AOG.0000000000002462

Fig. 4.

Fig. 4.

Change from baseline at end of treatment in Uterine Fibroid Symptom and Health-Related Quality of Life questionnaire (UFS-QOL) scores (intent-to-treat population). *P<.01, †P<.001 vs placebo. Error bars represent standard error. Analysis of covariance controlling for baseline score and pooled study site was used for change from baseline in UFS-QOL scores. Health-Related Quality of Life (HRQOL) Total score and HRQOL subscale scores range from 0 to 100; higher scores indicate better HRQOL. Symptom severity subscale score ranges from 0 to 100; higher scores indicate greater symptom severity. UPA, ulipristal acetate.